SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Abstract Background and aims Sodium tissue content by 23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular cells in a 1:1 fashion. We hypothesized that SGLT-2 inhibiti...

Full description

Bibliographic Details
Main Authors: M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder, R. E. Schmieder
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Cardiovascular Diabetology
Subjects:
Magnetic resonance imaging
Type 2 diabetes
SGLT-2 inhibition
Tissue sodium content
Online Access:http://link.springer.com/article/10.1186/s12933-017-0654-z

Internet

http://link.springer.com/article/10.1186/s12933-017-0654-z

Similar Items